Abstract: Primary central nervous system lymphoma (PCNSL) is a rare type of extranodal non⁃Hodgkin's lymphoma that exclusively involves the central nervous system (CNS）. Previous studies have shown that chimeric antigen receptor T (CAR⁃T) cell therapy can improve the depth of remission and survival outcomes in patients with PCNSL. CD19 CAR⁃T cell therapy has been successful in treating a various of B⁃cell lineage malignancies, but has been limited in treating B cell non⁃Hodgkin lymphoma presenting in the CNS, primarily due to potential toxicity. This paper reported a case of PCNSL who did not develop any grade of cytokine release syndrome or immune effector cell⁃related neurotoxicity syndrome after CD19 cell CAR⁃T cell therapy and achieved complete remission, and it can provide a reference for the clinical treatment of this type of patients.

Key words: Primary central nervous system lymphoma, CAR-T cell therapy, Cytokine release syndrome, Immune effector cell-related neurotoxicity syndrome